Some 90 percent of the human test subjects developed an immune response against HIV during the vaccines nine-month trial period.
The study was conducted by Karolinska Institute, Karolinska University Hospital and the Swedish Institute for Infectious Disease Control.
The vaccine, created from the virus’s gene pool, give cell nuclei the ability to produce antibodies against the virus that causes Aids.
“We are very pleased with the results so far, but we have a long way to go before we are finished,” said Eric Sandström, professor at Karolinska University Hospital to The Local.
“We will test the product this fall in Tanzania on a group of subjects with a different genetic background. We are very upbeat though.”
Side effects have been minimal in the Swedish trial. A few have reacted with headaches and fever, but it has been tolerable for most.
Some 40 million people are HIV infected globally. Each day, 16,000 are infected. An effective vaccine would be revolutionary.
“We have made it so extremely far when it comes to medicine, and it would be wonderful to be there and come up with a solution that doesn’t just concern the western world,” said Sandström.